Plain-language summary
Metabolic dysfunction-associated fatty liver disease currently has no approved drug treatment, and umbilical cord-derived mesenchymal stem cells are among the most actively studied candidates. This review goes beyond describing single pathways and instead builds an integrated multi-target synergy network in which these cells simultaneously regulate inflammation, metabolism, and fibrosis through the coordinated interaction of the AMPK/mTOR, Nrf2/HO-1, and TGF-beta/Smad pathways. The authors then systematically assess clinical trials published between 2022 and 2025 and identify persistent barriers to translation: the lack of agreed histological endpoints, batch-to-batch variability between cell products, and the absence of proper dose-ranging studies. They also incorporate developments from 2024 and 2025 that earlier reviews missed, including mitochondrial transfer through tunneling nanotubes with quantitative efficacy data, and emerging evidence on exosomal circular RNA networks. The review closes with concrete recommendations: standardized GMP manufacturing, mandatory genomic stability testing, and long-term safety registries for treated patients.
Key findings
- Umbilical cord-derived mesenchymal stem cells regulate inflammation, metabolism, and fibrosis in MAFLD through the coordinated AMPK/mTOR, Nrf2/HO-1, and TGF-beta/Smad pathways.
- Clinical trials from 2022 to 2025 still face barriers including the lack of histological endpoints, batch-to-batch variability, and missing dose-exploration studies.
- Recent findings highlight mitochondrial transfer through tunneling nanotubes and exosomal circular RNA networks as mechanisms not covered by earlier reviews.
- The authors recommend standardized GMP production, mandatory genomic stability testing, and long-term safety registration.
Original abstract
There is currently no approved drug treatment for metabolic dysfunction-related fatty liver disease (MAFLD). Umbilical cord-derived mesenchymal stem cells (UC-MSCs) show therapeutic potential, but their mechanism of action is remains incompletely understood. Different from previous reviews that focused on a single pathway, this article presents three important contributions: First, it constructs an integrated "multi-target synergy network" model, clarifying how UC-MSCs coordinate and regulate the inflammatory, metabolic and fibrotic processes through the interactions between the AMPK/mTOR, Nrf2/HO-1 and TGF-β/Smad pathways; Second, it systematically assesses recent clinical trials (2022-2025), identifying several unaddressed barriers to transformation, including the lack of histological endpoint indicators, batch-to-batch differences, and the absence of dose exploration studies; Third, we integrate the latest developments from 2024 to 2025, particularly mitochondrial transfer (mediated by tunnel nanotubes and accompanied by quantitative efficacy data) and exosome circular RNA networks [Formula: see text], which have not been covered in previous reviews. Based on the above analysis, we also propose specific suggestions for standardized GMP production, mandatory genomic stability testing, and long-term safety registration. This review provides a comprehensive analysis of elaborates on the treatment of MAFLD with UC-MSCs from a mechanistic and translational perspective, based on the extensive updates of relevant literature.
Frequently asked questions
What did this study find?
Metabolic dysfunction-associated fatty liver disease currently has no approved drug treatment, and umbilical cord-derived mesenchymal stem cells are among the most actively studied candidates. This review goes beyond describing single pathways and instead builds an integrated multi-target synergy network in which these cells simultaneously regulate inflammation, metabolism, and fibrosis through the coordinated interaction of the AMPK/mTOR, Nrf2/HO-1, and TGF-beta/Smad pathways. The authors then systematically assess clinical trials published between 2022 and 2025 and identify persistent barriers to translation: the lack of agreed histological endpoints, batch-to-batch variability between cell products, and the absence of proper dose-ranging studies. They also incorporate developments from 2024 and 2025 that earlier reviews missed, including mitochondrial transfer through tunneling nanotubes with quantitative efficacy data, and emerging evidence on exosomal circular RNA networks. The review closes with concrete recommendations: standardized GMP manufacturing, mandatory genomic stability testing, and long-term safety registries for treated patients.
Was this tested in humans or in the laboratory?
This paper reports a clinical study in human participants.
Where can I read the original paper?
The full text lives with the publisher: https://doi.org/10.1007/s12015-026-11181-x
How to cite this paper
Jiang Hua, Wang Hui, Zhu Yankun, Yi Chunyan, Liu Jinli, Zhao Ruisi et al.. Human Umbilical Cord Mesenchymal Stem Cells in Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) Therapy: Mechanisms, Clinical Efficacy, and Future Perspectives.. Stem cell reviews and reports. 2026, 2026-07-16. DOI: 10.1007/s12015-026-11181-x
Source & verification
- Journal: Stem cell reviews and reports
- Published: 16 July 2026
- DOI: 10.1007/s12015-026-11181-x
- PubMed ID: 42461490
- Indexed via: pubmed
- MeSH terms: Humans, Mesenchymal Stem Cells, Umbilical Cord, Mesenchymal Stem Cell Transplantation, Non-alcoholic Fatty Liver Disease, Metabolic Diseases, Animals, Fatty Liver